PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide

Inclusion Criteria: * written informed consent * 18 years ≤ age ≤ 35 years on the day of the first visit * 22.0 ≤ BMI ≤ 28.0 kg/m2 * (History of) good physical and mental health as determined by history taking, physical and laboratory examinations and ECG. * fasting glucose level of \< 5.6 mmol/L, in addition to a glucose level of \< 7.8 mmol/L at 2 hours after intake of 75 g glucose (OGTT). * able to keep a normal day and night rhythm during the trial period (i.e. no shift work) Exclusion Criteria: * history or presence of a medical disorder * use of drugs, except for incidental (non-opioid) analgesic agents * first degree relative with T2DM * performing intensive physical activity \> 1x/week * an allergic or anaphylactic reaction to prednisolone treatment in the past * clinically relevant history or presence of any medical disorder, which are mentioned in the Summary of Product Characteristics (SPC) as contraindication for the use of prednisolone * glucocorticosteroid use during the last three months prior to the first dose * participation in an investigational drug trial within 90 days prior to the first dose * donation of blood (\> 100 mL) within 90 days prior to the first dose * history of or current abuse of drugs or alcohol (\>14 U/week) * smoking * use of grapefruit products during the study period * recent changes in weight and/or physical activity * serious mental impairment or language problems i.e. preventing to understand the study protocol/aim